This innovative project addresses a critical need in hearing disorders research by developing advanced pharmacological screening tools, positioned as intermediaries between traditional cell lines and animal models. The aim is to transpose and optimize the previously established protocol for obtaining inner ear organoids by integrating CTIBIOTECH™ 3D bioprinting technology, thus guaranteeing reproducibility, optimal quality and yield, and industrialization in the medium term to contribute to CILCARE's development and business.
Protocols have been developed by the Bioengineering and Nanosciences Laboratory (LBN) at the University of Montpellier enabling the design and production of inner ear organoids from hiPSCs. The CTIBIOTECH™ teams were selected by SATT AxLR for their unique expertise in 3D bioprinting, the fruit of over 15 years of R&D in human tissue biomanufacturing to facilitate the translation and industrial production of this technology at CILCARE.
Having demonstrated its ability to mass-produce complex human skin models - recently including the first computer-connected skin with sensory nervous system - CTIBIOTECH™ will now apply its bioproduction, bio-extrusion additive manufacturing and automation technologies to inner ear organoids. CTIBIOTECH™, by facilitating a highly advanced non-animal NAMs (New Approach Methods) alternative in the hearing disorders sector, strengthens its position at the forefront of a cell-based bioassay market estimated at 28 billion euros by 2028, (CAGR > 7%).
Professor Colin McGUCKIN, President and Chief Scientific Officer of CTIBIOTECH™, noted: "We are honored to have been selected for this pioneering project. Inner ear organoids represent one of the most sophisticated models in tissue engineering, and we are convinced that our bioprinting automation approach will significantly accelerate research into hearing disorders."
Dr. Nico FORRAZ, Chief Executive Officer of CTIBIOTECH™, emphasized the strategic importance of this agreement: "Working alongside CILCARE and SATT AxLR, we are helping to develop tools that will accelerate the discovery of treatments for hearing pathologies affecting more than 1 billion people worldwide. This collaboration fits in perfectly with our strategy of reducing drug development costs and time through innovation in automation."
Hearing disorders are a growing global public health issue. According to the World Health Organization, one in four people will be affected by hearing loss by 2050, and over a billion young people are already at high risk due to unsafe listening practices, notably via the prolonged use of high-volume headphones.
Beyond the individual impact - on quality of life, mental health, cognitive abilities and social integration - the economic consequences are considerable. The WHO estimates the global cost of unmanaged hearing loss at $980 billion a year, including lost productivity, special education and healthcare costs.
However, to date, no pharmacological treatment exists to prevent or restore hearing loss. Hearing aids and implants can improve sound perception, but do not target the biological causes and remain only partially effective, particularly in noisy environments. In this context, the development of innovative therapeutic solutions is an urgent and strategic public health priority.
The development of 3D bioprinted inner ear organoids represents a major step forward to:
- Accelerate pharmacological screening: standardized, reproducible models will enable rapid testing of new drug candidates;
- Reduce animal testing: An ethical and more predictive alternative for research into hearing disorders;
- Improve clinical relevance: Human organoids offer superior predictive power to traditional mouse models;
- Industrialize production: 3D bioprinting will enable mass production with consistent quality.
"Organoids are set to become essential tools in medical research. The research program financed by SATT AxLR and the support of CTIBIOTECH, in this key stage, will enable Cilcare to accelerate the development of new therapeutic solutions and thus become the leader in the treatment of hearing pathologies." - Philippe Nérin President of SATT AxLR
"Organoids are changing the way we think about preclinical research: they reduce the time needed to discover and validate new therapies, while improving their biological relevance. This is a key step towards faster, more responsible medical innovation," comments Sylvie Pucheu, Director of Preclinical Innovation and co-founder of Cilcare.
About CTIBIOTECH™
CTIBIOTECH™ is a biotechnology company specializing in the development of advanced human tissue models for research, drug discovery and cosmetic testing. Using state-of-the-art bioprinting and tissue engineering techniques, CTIBIOTECH creates highly realistic and functional human tissue models that offer superior predictive power and ethical alternatives to traditional testing methods.
For more information please visit, www.ctibiotech.com
